Financials data is unavailable for this security.
View more
Year on year Pak Fah Yeow International Ltd grew revenues 76.06% from 147.20m to 259.16m while net income improved 250.66% from 29.96m to 105.04m.
| Gross margin | 87.05% |
|---|---|
| Net profit margin | 36.37% |
| Operating margin | 46.00% |
| Return on assets | 10.44% |
|---|---|
| Return on equity | 12.78% |
| Return on investment | 11.32% |
More ▼
Cash flow in HKDView more
In 2023, Pak Fah Yeow International Ltd increased its cash reserves by 78.83%, or 115.79m. The company earned 147.90m from its operations for a Cash Flow Margin of 57.07%. In addition the company generated 16.65m cash from investing, though they paid out 48.96m more in financing than they received.
| Cash flow per share | 0.3329 |
|---|---|
| Price/Cash flow per share | 7.75 |
| Book value per share | 2.41 |
|---|---|
| Tangible book value per share | 2.40 |
More ▼
Balance sheet in HKDView more
| Current ratio | 4.35 |
|---|---|
| Quick ratio | 4.22 |
| Total debt/total equity | 0.0055 |
|---|---|
| Total debt/total capital | 0.0055 |
More ▼
Growth rates in HKD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 11.48% and 250.66%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is the above the industry average.
| Div yield(5 year avg) | 4.08% |
|---|---|
| Div growth rate (5 year) | -8.06% |
| Payout ratio (TTM) | 69.47% |
| EPS growth(5 years) | 23.02 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 9.37 |
More ▼
